Compare Allstate Corp (ALL) vs Hims and Hers Health Inc (HIMS) Price & Performance

Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.

The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.

Hims & Hers Health trades at $34.38, down 3.02% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights expansion in weight-loss therapies and a $400 million JPMorgan facility for financial flexibility, as the stock recovers from earlier regulatory concerns.

The outlook is cautiously optimistic, driven by growth in GLP-1 products and international expansion, but high valuation ratios and projected 2026 losses pose risks. Analyst consensus is a 'Hold' with a $33.57 price target, suggesting limited near-term upside from current levels amid competitive and execution challenges.